WO2000042986A2 - Künstliche tränenflüssigkeit in gelform - Google Patents
Künstliche tränenflüssigkeit in gelform Download PDFInfo
- Publication number
- WO2000042986A2 WO2000042986A2 PCT/EP2000/000369 EP0000369W WO0042986A2 WO 2000042986 A2 WO2000042986 A2 WO 2000042986A2 EP 0000369 W EP0000369 W EP 0000369W WO 0042986 A2 WO0042986 A2 WO 0042986A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ophthalmic composition
- composition according
- gel
- preparation
- components
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Definitions
- the natural tear fluid which is formed by the lacrimal glands of the eye, serves to moisten the cornea of the eye and to flush out foreign particles.
- an artificial tear fluid is used to support or replace the natural tear fluid, which reduces local irritation by forming a fluid film on the surface of the eye and reduces the risk of inflammation.
- such artificial tears contain viscosity-increasing substances to prolong contact with the cornea, isotonic auxiliaries and buffers to adjust physiologically compatible conditions, and preservatives to ensure adequate sterility and stability of the preparation.
- compositions are known for artificial tear fluids.
- An artificial tear fluid is obtained, for example, by dissolving polyvinyl alcohol or polyvinyl pyrrolidone in water, optionally with the addition of salts and preservatives.
- Cellulose derivatives and polyacrylamides are also often used in artificial tear fluids.
- the preparations based on these substances are usually liquids with slightly increased viscosities of 10 to 60 mPas-s, at most 100 mPas-s.
- Liquids due to their longer dwell time on the eye generally have the serious disadvantage that gels have different refractive indices than the natural eye liquid, which, when used on the eye, can result in optical distortions which occur for a limited time after application adversely affect visual acuity.
- Effects is for making artificial tear fluids in gel form, Especially in the case of gels with a longer dwell time on the eye, the setting of a certain refractive index range is desirable.
- the object of the present invention is to provide a long-term stable, drippable gel for use as an artificial tear fluid, in particular for prolonged use
- dwell time on the eye which does not impair the field of vision of the eye, reduces and / or excludes optical distortions, does not cause eye irritation, in particular if the dwell time is extended, and remains stable over long periods of time.
- gels based on xanthan have a significantly increased stability with regard to viscosity and refractive index.
- So xanthan solutions can be stabilized with about 0.5% electrolytes in such a way that both the viscosity and the optical properties, such as the refractive index, over a longer period and over a wide temperature range from 0 ° C to boiling temperature, preferably 0 ° C to 50 ° C and particularly preferably from 0 ° C to 40 ° C, remain almost unchanged.
- the ophthalmic composition is particularly preferably complexing agents, preferably ethylenediaminetetraacetic acid and its salts
- EDTA Sodium edetate
- xanthan refers in particular to the heteropolysaccharides which are formed by the microorganism Xanthomonas campestris.
- gel-forming, natural polysaccharides which can be used according to the invention also include guar gum, gellan gum, carragenane,
- the content of gel-forming polysaccharide in the artificial tear fluid according to the invention is 0J to 3% by weight, preferably 0.5 to 1.5% by weight.
- the content of preservative, preferably benzododecinium chloride, in the artificial tear fluid according to the invention is 0.001 to 0.1% by weight, preferably 0.01% by weight.
- Ophthalmic compositions according to the invention in the form of aqueous gel preparations have a viscosity of 1 to 5000 mPas-s, preferably 300 to 3000 mPas-s, and particularly preferably 700 to 2000 mPas-s.
- the ophthalmic compositions according to the present invention generally have eye dwell times of greater than 1 hour, preferably greater than 2 hours and particularly preferably 2 to 3 hours.
- the ophthalmic composition according to the invention can advantageously also be used as a carrier material for a wide variety of ophthalmic active ingredients.
- the aqueous gel preparation is prepared in a preferred manner
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU27974/00A AU2797400A (en) | 1999-01-19 | 2000-01-18 | Artificial lacrimal fluid in gel form |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19901931.2 | 1999-01-19 | ||
DE19901931 | 1999-01-19 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000042986A2 true WO2000042986A2 (de) | 2000-07-27 |
WO2000042986A3 WO2000042986A3 (de) | 2000-11-30 |
WO2000042986A8 WO2000042986A8 (de) | 2001-06-21 |
Family
ID=7894719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/000369 WO2000042986A2 (de) | 1999-01-19 | 2000-01-18 | Künstliche tränenflüssigkeit in gelform |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2797400A (de) |
DE (1) | DE20022450U1 (de) |
WO (1) | WO2000042986A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1358883A1 (de) * | 2002-04-30 | 2003-11-05 | Sifi S.p.A | Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4120949A (en) * | 1977-10-05 | 1978-10-17 | Cooper Laboratories, Inc. | Ophthalmic solution |
US4136177A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Xanthan gum therapeutic compositions |
EP0183457A2 (de) * | 1984-11-23 | 1986-06-04 | FISONS plc | Wässriges Natriumcromoglycat enthaltende Mittel |
US5188826A (en) * | 1988-02-08 | 1993-02-23 | Insite Vision Incorporated | Topical ophthalmic suspensions |
WO1995020971A1 (en) * | 1994-02-02 | 1995-08-10 | Stichting Voor De Technische Wetenschappen | Therapeutic composition for replacing and/or supplementing body fluids |
EP0770383A1 (de) * | 1995-10-24 | 1997-05-02 | Dr. GERHARD MANN chem.-pharm. Fabrik GmbH | Ophthalmische Cromolyn-Gelzubereitung |
US5895645A (en) * | 1995-01-31 | 1999-04-20 | Bausch & Lomb Incorporated | Opthalmic solution for artificial tears |
WO1999051273A1 (en) * | 1998-04-07 | 1999-10-14 | Alcon Laboratories, Inc. | Gelling ophthalmic compositions containing xanthan gum |
-
2000
- 2000-01-18 DE DE20022450U patent/DE20022450U1/de not_active Expired - Lifetime
- 2000-01-18 AU AU27974/00A patent/AU2797400A/en not_active Abandoned
- 2000-01-18 WO PCT/EP2000/000369 patent/WO2000042986A2/de active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4136177A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Xanthan gum therapeutic compositions |
US4120949A (en) * | 1977-10-05 | 1978-10-17 | Cooper Laboratories, Inc. | Ophthalmic solution |
EP0183457A2 (de) * | 1984-11-23 | 1986-06-04 | FISONS plc | Wässriges Natriumcromoglycat enthaltende Mittel |
US5188826A (en) * | 1988-02-08 | 1993-02-23 | Insite Vision Incorporated | Topical ophthalmic suspensions |
WO1995020971A1 (en) * | 1994-02-02 | 1995-08-10 | Stichting Voor De Technische Wetenschappen | Therapeutic composition for replacing and/or supplementing body fluids |
US5895645A (en) * | 1995-01-31 | 1999-04-20 | Bausch & Lomb Incorporated | Opthalmic solution for artificial tears |
EP0770383A1 (de) * | 1995-10-24 | 1997-05-02 | Dr. GERHARD MANN chem.-pharm. Fabrik GmbH | Ophthalmische Cromolyn-Gelzubereitung |
WO1999051273A1 (en) * | 1998-04-07 | 1999-10-14 | Alcon Laboratories, Inc. | Gelling ophthalmic compositions containing xanthan gum |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1358883A1 (de) * | 2002-04-30 | 2003-11-05 | Sifi S.p.A | Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen |
WO2003092706A1 (en) * | 2002-04-30 | 2003-11-13 | Sifi S.P.A. | Re-epithelializing pharmaceutical compositions comprising xanthan gum |
EP1913948A1 (de) * | 2002-04-30 | 2008-04-23 | Sifi S.p.A | Reepithelialisierende pharmazeutische Zusammensetzungen, die Xanthangummi enthalten |
AU2003230224B2 (en) * | 2002-04-30 | 2008-07-17 | Sifi S.P.A. | Re-epithelializing pharmaceutical compositions comprising xanthan gum |
US8912164B2 (en) | 2002-04-30 | 2014-12-16 | Sifi S.P.A. | Re-epithelializing pharmaceutical compositions comprising xanthan gum |
Also Published As
Publication number | Publication date |
---|---|
DE20022450U1 (de) | 2002-01-17 |
WO2000042986A8 (de) | 2001-06-21 |
AU2797400A (en) | 2000-08-07 |
WO2000042986A3 (de) | 2000-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69818675T2 (de) | Galaktomannanpolymere und borat enthaltende augenarzneimittel | |
DE60117009T2 (de) | Verwendung einer wässrigen Lösung zur Behandlung von Trockenaugen | |
DE69333850T3 (de) | Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen | |
DE3238820C2 (de) | ||
DE2448871C3 (de) | Stabilisierung von trans-Retinsäurecreme | |
EP0801948B1 (de) | Ophtalmische Zusammensetzung mit verlängerter Verweilzeit am Auge | |
DE19511322C2 (de) | Sterile Augengele mit einem Gehalt an mittelkettigen Triglyceriden und Verfahren zu deren Herstellung | |
CH629385A5 (de) | Arzneimitteltraeger zum aufbringen einer kompatiblen, pharmakologisch aktiven, chemischen substanz auf eine schleimhaut. | |
EP2532370A2 (de) | Farbstofflösung | |
DE102005055275A1 (de) | Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung | |
WO2001060394A1 (de) | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung | |
DE602004008651T2 (de) | Flüssige zubereitung für kontaktlinsen | |
DE60221227T2 (de) | Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen | |
DE69333005T2 (de) | Zusammensetzungen von hyaluronat mit bimodalem molekulargewicht und verfahren zu deren verwendung | |
DE69828451T2 (de) | Wässrige ophthalmische formulierungen mit chitosan | |
EP0166971A1 (de) | Insulinzubereitungen, Verfahren zu deren Herstellung und deren Verwendung | |
EP3843698B1 (de) | Milde reinigungszubereitung | |
WO2000042986A2 (de) | Künstliche tränenflüssigkeit in gelform | |
DE60212542T2 (de) | Injektionslösung enthaltend ein Kolloid aus Eisen und Haiknorpel-Chondroitinsulfat | |
DE60106619T2 (de) | Pharmazeutische zusammensetzungen enthaltend tobramycin und xanthangummi | |
DE19539532C2 (de) | Ophthalmisches Cromoglicat-Gelpräparat | |
DE2714676A1 (de) | Augentropfenloesung | |
DE19830914C1 (de) | Verfahren zur Herstellung einer Proteinlösung | |
DE2336546C2 (de) | Diagnostisches Mittel, das zur Einführung in Körperhöhlen geeignet ist | |
DE2201669C3 (de) | Pyrogenfreier Blutplasmaersatz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i | ||
122 | Ep: pct application non-entry in european phase | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |